29 results
8-K
EX-99.1
BGNE
BeiGene Ltd
15 Sep 22
Additional poster presentations show breadth of tislelizumab global clinical development program as single-agent treatment and in combination
4:37pm
analysis of Asian versus non-Asian patients in the global RATIONALE 303 study of tislelizumab versus docetaxel as second- or third-line therapy … for tislelizumab versus docetaxel (41.1% vs 75.2% of Asian patients and 45.9% vs 72.9% of non-Asian patients, respectively).
Abstract 1017P –AdvanTIG-105
8-K
EX-99.1
qrv57ylasl49b
25 Aug 22
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
4:18pm
8-K
EX-99.1
cf2zoyrjb36fg kwfm7
30 Jun 22
Other Events
4:17pm
8-K
EX-99.2
mbjed1nt52o32e8vt98c
14 Jun 22
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
5:16pm
8-K
EX-99.2
q2jvil8kbiobvkpk3
28 Apr 22
Results of Operations and Financial Condition
4:06pm
8-K
EX-99.1
ymz502mj8yfsd
14 Dec 21
BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021
8:16am
8-K
EX-99.2
3s1eyt0ah ifff5gqb24
6 Dec 21
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
4:16pm
8-K
EX-99.2
231eh1yw6
16 Nov 21
Results of Operations and Financial Condition
9:07am
8-K
EX-99.1
0j0v6fe5jq2o5nef6hp
26 Aug 21
Other Events
4:19pm
8-K
EX-99.1
ux4d 7ick
24 Aug 21
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer
4:31pm
8-K
EX-99.2
9fja5nj
21 May 21
BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma
4:06pm
8-K
EX-99.1
eff3ijmo6bu
2 Oct 19
Other Events
4:16pm